The nation of Zimbabwe has declined a substantial US healthcare agreement worth $367m (£272m) over five years due to the United States' insistence on confidential biological samples.
The decision came to light following a internal memorandum dated December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesperson later explained that the United States was demanding access to genetic material for research and profit while refused to share the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for more negotiations to find a agreement acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court halted a related deal with the US after concerns were raised about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral deals to enhance openness and accountability.
Based on statements, 16 nations in Africa have to date signed these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Agreement
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its genetic material and health information indefinitely, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could result from that shared data," Mangwana explained.
"In essence, our country would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our population if a future health crisis emerge."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one health agreements were disrupting frameworks previously established via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This framework is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further discussions with our US partners on how subsequent collaboration might be arranged in a way that respects the independence and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but urged that talks must proceed since a large portion of the nation's HIV programmes were funded by international support.
"In cases where technical issues exist, including those involving information security or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," the group added.
The situation emphasises the ongoing tensions between receiving crucial international aid and safeguarding a country's data in an increasingly data-driven world.